Analyst Picks & Changes

Analyst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 4/21 cls
Acorda Therapeutics Inc. (NASDAQ:ACOR) RBC Capital Markets Michael Yee Price target Market outperform -5% $27.56
Yee raised his target to $38 from $32 after the U.S. Patent and Trademark Office allowed a patent application on the composition of Acorda's multiple sclerosis drug Ampyra dalfampridine. The claims of the application, No. 11/010,828, relate to

Read the full 802 word article

How to gain access

Continue reading with a
two-week free trial.